Calmark signs distributor agreement with ILS Danmark
Calmark Sweden AB (publ) has entered an exclusive distributor agreement with the company ILS Danmark regarding marketing and sales of the Calmark POC system on the Danish market. The agreement provides Calmark with an additional well-established partner on the important domestic market.
ILS Danmark has more than 20 years of experience in distributing products and services to the Danish health care and laboratories. The company focuses on medical analysis instruments, primarily for hospital laboratories but also for the manufacturing industry. ILS is active in the customer segments that are important to Calmark, and sells, among other things, products for coagulation diagnostics to the Danish hospitals.
"ILS Danmark is exactly the kind of distributor that we are looking to work with; they are specialized in diagnostics, and they attach great importance to staying close to the customer and providing the best possible support and service, which we find very positive," says Magdalena Tharaldsen, Director International Business Development of Calmark.
"I am very proud that we have signed distributor agreements covering all the large Nordic markets," says Anna Söderlund, CEO of Calmark. "We are looking forward to the cooperation with such a well-established distributor in Denmark."
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark develops a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.
